A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.

Challenge

While disease progression in MASH is associated with worsening clinical outcomes, its impact on patient-reported quality of life—across multiple symptom and functional domains using a validated, disease-specific instrument—had not been characterized prospectively in a real-world US cohort.

Solution

A cross-sectional analysis of NASH-CHECK survey data from TARGET-NASH patients across MASL, MASH, and cirrhosis subgroups was conducted, using regression models to isolate the effect of disease severity on each PRO domain while controlling for demographic and metabolic covariates.

Impact

Demonstrating significant PRO deterioration across 7 of 9 NASH-CHECK domains with advancing liver disease severity provides clinical meaningfulness anchor data for MASH endpoint design and supports regulatory arguments that disease modification translates into patient-relevant benefit.